Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance
Wiesel, F.A.
British Journal of Psychiatry. Suppl 23: 65-70
1994
ISSN/ISBN: 0960-5371 PMID: 7913609 Document Number: 425667
Neuroleptic drugs have been used in the treatment of schizophrenic patients for 40 years. In the 1960s it was proposed that the mechanism of action was a blockade of dopamine receptors; in vivo studies give strong evidence that a blockade of D2 dopamine receptors mediate the antipsychotic effect of classic neuroleptics. However, the antipsychotic effect of neuroleptics is synergistic with family treatment and social-skills training.
Document emailed within 1 workday
Related Documents
Sayed, Y.; Garrison, J.M. 1983: The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs--a review Psychopharmacology Bulletin 19(2): 283-2882009: Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents Prescrire international 18(104): 251
Mizuno, M. 2009: Clinical significance and reality in early intervention for patients with schizophrenia Seishin Shinkeigaku Zasshi 111(3): 272-273
Verdeau-Pailles, J. 1976: Treatment of the neuroleptic syndrome by biperiden hydrochloride under its delayed-action form. a 9-month study on 55 hospitalized patients L'Encephale 2(4): 341-347
Ryzhakov, B.A.; Nuller, I.U. 1992: The use of the bromocriptine test in schizophrenia patients resistant to neuroleptic therapy Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 92(3): 79-80
Musaev, A.V.; Guseĭnova, S.G. 1992: The clinical and neuromediator mechanisms of the analgetic action of decimeter waves and deresinated naphthalan in patients with humeroscapular periarthrosis Voprosy Kurortologii Fizioterapii i Lechebnoi Fizicheskoi Kultury 4: 21-25
Youle, R J. 2003: Haya Lorberboum-Galski and Philip Lazarovici (Eds.). Chimeric Toxins: Mechanisms of Action and Therapeutic Applications (Cell and Molecular Mechanisms of Toxin Action) International Journal of Toxicology 22(4): 331-332
Becker, R.E.; Singh, M.M.; Meisler, N.; Shillcutt, S. 1985: Clinical significance, evaluation, and management of secondary depression in schizophrenia Journal of Clinical Psychiatry 46(11 Part 2): 26-32
Janssen, P.A.; Niemegeers, C.J.; Schellekens, K.H. 1965: Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquillizers) from Animal Data?i. "neuroleptic Activity Spectra" for Rats Arzneimittel-Forschung 15: 104-117
Cocchi, R.; Fusari, A.; Lorini, G.; Roccia, L. 1977: Acupunctura, "vital" drugs and psychopharmacological agents in the treatment of psychiatric patients with deep depressive disorders, with considerations on the probable neurophysiological mechanisms of the synergism of action Minerva Medica 68(33): 2309-2314
Olajossy, M.; Chlewiński, Z.; Hunca-Bednarska, A.; Bednarski, M. 1982: Emotional significance of ideas in patients with chronic schizophrenia Psychiatria Polska 16(5-6): 359-363
Marneros, A. 1984: Do 1st rank symptoms establish the diagnosis of schizophrenia? on the significance of clinical correlations and the limits of criteria Der Nervenarzt 55(7): 365-370
Schooler, N.R.; Keith, S.J.; Severe, J.B.; Matthews, S. 1989: Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 331-335
Rosenbaum, B.; Bechgaard, B.; Borberg, S.; Burgaard, L.; Lauritsen, L.; Lindhardt, A.; Laerum, H.; Nystrup, J.; Winther, G. 1991: Psychotherapy of patients with schizophrenia. Study of the significance of group supervision Ugeskrift for Laeger 153(40): 2822-2825
Lisoprawski, A. 1983: Drug abuse experience and neuroleptic prescriptions at the onset of schizophrenia La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 59(25): 1925-1927
Møller, P. 1995: Positive and negative psychotic symptoms in schizophrenia. Clinical significance and benefits in the light of the history of classification Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 115(20): 2529-2532
Govorin, N.V.; Lozhkina, A.N. 1991: Antibodies to neuroleptics and their role in the mechanisms of the development of drug resistance in psychopharmacotherapy of patients with paranoid schizophrenia Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 91(7): 117-121
Damulin, I.V. 2009: Neuroplasticity: main mechanisms and their clinical significance Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 109(4): 4-8
Mintz, M.; Tomer, R.; Myslobodsky, M.S. 1982: Neuroleptic-induced lateral asymmetry of visual evoked potentials in schizophrenia Biological Psychiatry 17(7): 815-828
Flaegstad, T. 1989: Chronic virus infections. Mechanisms and clinical significance Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 109(4): 433-435